en.Wedoany.com Reported - The Department of Nuclear Medicine at Zhejiang Cancer Hospital recently initiated an international multicenter clinical research project targeting advanced prostate cancer with 225Ac-PSMA (Actinium-225) targeted alpha radionuclide therapy, and has completed the first patient dosing within Zhejiang Province. The launch of this project marks the first clinical study of such technology in Zhejiang, representing new progress in the field of targeted alpha radionuclide therapy for advanced prostate cancer. Additionally, this project signifies that Zhejiang Cancer Hospital has officially joined the international frontier radionuclide therapy research collaboration system, transitioning from a phase of learning and following to participating in international multicenter joint research.
Professor Zhang Hong, Deputy Secretary of the Party Committee, Executive President of the hospital, and Academic Leader of the Department of Nuclear Medicine, stated that the hospital adheres to a patient-centered approach and actively introduces internationally advanced nuclear medicine diagnostic and therapeutic technologies to provide new treatment options for advanced cancer patients who have failed multiple lines of therapy. With advancements in medical technology, cancer is gradually transforming into a chronic disease that can be managed long-term, and some patients can achieve long-term survival with tumors after receiving new treatment methods. As the leading construction unit of the National Cancer Regional Medical Center, Zhejiang Cancer Hospital will continue to promote research on internationally advanced diagnostic and therapeutic technologies, such as novel targeted radionuclide drugs, for various indications including head and neck tumors, thoracic tumors, abdominal tumors, prostate cancer, and bone tumors.
The first patient to receive 225Ac-PSMA targeted radionuclide therapy is a 67-year-old male with prostate cancer, diagnosed over two years ago. The patient had previously undergone surgery and endocrine therapy, but the disease has now progressed with multiple bone metastases. Chief Physician Yi Heqing led the medical team in a comprehensive review of the patient's medical history, imaging data, and laboratory results. Given the patient's failure of multiple lines of therapy and heavy burden of bone metastases, the team organized intra-departmental discussions and a multidisciplinary MDT consultation involving the Department of Nuclear Medicine and the Department of Urology, repeatedly comparing and weighing the benefits and risks of various radionuclide treatment regimens. After multiple rounds of evaluation, the team unanimously agreed that 225Ac-PSMA targeted alpha radionuclide therapy was the most suitable option for this patient. The patient successfully received intravenous drug infusion in the hospital's nuclear medicine ward, with stable vital signs and good overall condition throughout the treatment process.
In the field of radionuclide therapy for advanced prostate cancer, beta radionuclide regimens represented by 177Lu-PSMA have entered clinical practice. Chief Physician Yi Heqing pointed out that the alpha radionuclide 225Ac offers significant advantages over beta radionuclides, with higher energy and a shorter range. It can directly break the double-strand DNA of tumor cells, resulting in more thorough killing effects, and does not exhibit complete cross-resistance with beta radionuclide therapy, providing a new treatment option for drug-resistant patients. The therapeutic energy is highly concentrated within the tumor lesions, efficiently killing cancer cells while maximally protecting the bone marrow and surrounding normal tissues of organs, balancing efficacy and safety. Currently, this therapy has not yet been approved for routine clinical use in China. Its implementation in the form of a clinical trial indicates that the hospital possesses the complete capacity to transition from research to clinical application. Furthermore, as a demonstration center for integrated radionuclide diagnosis and treatment of prostate cancer, the hospital routinely conducts radionuclide treatment regimens such as 177Lu-PSMA, which are already approved for marketing in China. For patients who do not meet the enrollment criteria for this clinical trial, other regimens can be evaluated within the same diagnostic and treatment framework, ensuring continuity of care.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
